MedTrace Logo

INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study

NCT04346537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2022-07-14

Study results available
· View outcomes & findings →

Summary

The objective of this study is it to confirm the safety and effectiveness of the INGEVITY+ Active Fixation Pace/Sense Lead.

Conditions

  • Bradycardia

Interventions

DEVICE

INGEVITY+™ Pace/Sense Lead

The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Devi Nair, MD · Arrhythmia Research Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2021-03-01
Completion
2021-03-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346537 on ClinicalTrials.gov